GES - Guess', Inc.
| Previous Close | 16.64 |
| Open | 16.71 |
| Bid | 16.64 x 1300 |
| Ask | 16.84 x 800 |
| Day's Range | 16.70 - 16.89 |
| 52 Week Range | 13.88 - 26.95 |
| Volume | 22,824 |
| Avg. Volume | 2,379,450 |
| Market Cap | 1.208B |
| Beta (3Y Monthly) | 0.84 |
| PE Ratio (TTM) | 105.38 |
| EPS (TTM) | 0.16 |
| Earnings Date | Aug 27, 2019 - Sep 3, 2019 |
| Forward Dividend & Yield | 0.45 (2.70%) |
| Ex-Dividend Date | 2019-06-18 |
| 1y Target Est | 22.50 |
- Zacks•4 days ago
Can High Costs Hurt Columbia Sportswear's (COLM) Q2 Earnings?
Columbia Sportswear's (COLM) Q2 performance is likely to gain from strong brands and DTC business; rising SG&A costs are a concern.
- Zacks•4 days ago
Activewear & School Goers to Boost Apparel Spending: 4 Picks
Consumers have developed a special liking for comfortable and fashionable brand of clothes termed as activewear.
- Zacks•6 days ago
Casey's General Stores, Michaels, lululemon athletica, Guess' and Under Armour highlighted as Zacks Bull and Bear of the Day
Casey's General Stores, Michaels, lululemon athletica, Guess' and Under Armour highlighted as Zacks Bull and Bear of the Day
- Zacks•7 days ago
Here's Why lululemon's a Hot Investment Pick Right Now
lululemon (LULU) is benefiting from product innovation, enhancement of omni-channel experience and sturdy international growth. It is also progressing well on the Power of Three strategic plan.
- Business Wire•7 days ago
Introducing the Fall 2019 GUESS Accessories Collection Advertising Campaign
This season, GUESS introduces a fresh accessories campaign shot in Los Angeles, CA by photographers Claudia and Ralf Pulmanns and art directed by Paul Marciano, Chief Creative Officer for GUESS?, Inc.
- Business Wire•7 days ago
Introducing the GUESS Fall 2019 Advertising Campaign
This Fall, GUESS is proud to feature Italian model Stefano Sala alongside Moscow native Iuliia Vasileva and London local Emily Deyt-Aysage in a breathtaking advertising campaign photographed on the island of Capri in Italy, wearing the latest denim trends that tells the story of GUESS’ denim heritage and roots of the brand.
- Zacks•8 days ago
Ralph Lauren Hurt by Weak North America Unit: Can It Recover?
Softness in Ralph Lauren's (RL) North America segment and adverse currency rates are hurting growth. But, the Next Great Chapter plan and strength in international and digital businesses bode well.
- Zacks•8 days ago
Zacks.com featured highlights include: Guess?, Denny's, FTI Consulting, Oaktree Capital and RenaissanceRe
Zacks.com featured highlights include: Guess?, Denny's, FTI Consulting, Oaktree Capital and RenaissanceRe
- Zacks•11 days ago
Does Market Volatility Bother You? 5 Low-Beta Stocks to Buy
We create a strategy that shows low-risk stocks can generate handsome returns if some parameters are considered.
- Zacks•13 days ago
Zacks.com featured highlights include: Guess, Party City, Shoe Carnival, Genesis and Restoration Robotics
Zacks.com featured highlights include: Guess, Party City, Shoe Carnival, Genesis and Restoration Robotics
- Zacks•14 days ago
Rising P/E: An Overlooked Trick to Land on 5 Winning Stocks
Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.
- InvestorPlace•22 days ago
7 Stocks on Sale the Insiders Are Buying
[Editor's Note: This article is updated each week with the latest insider moves.] The SEC has established numerous rules over the years to protect investors, including measures that prevent insiders from buying to take advantage of nonpublic information. Insiders have access to confidential information about a company. Sometimes that information could move the stock price once it goes public.For example, if an insider knows the company is about to announces earnings that are greater than estimated, the insiders could secretly buy options or shares.InvestorPlace - Stock Market News, Stock Advice & Trading TipsFortunately for us "outsiders," the SEC requires that insiders publicly disclose when they make a transaction in their company's stock. This means that we can find out when the insiders are buying. This can be a great indicator, especially if the price has recently made a large move downwards.This is because there are many reasons why an officer or a director of a company may decide to sell their stock -- they could simply need the money -- but an insider will only buy a stock for one reason! They believe that the stock is undervalued and that they will make a profit. * 7 F-Rated Stocks to Sell for Summer Due to the significant insider buying that has recently occurred, these stocks came up on my radar screen as potential investments to consider. Stocks to Buy With Insider Buying: Carnival Corp (CCL)Carnival Corp (NYSE:CCL) is a cruise ship company. The headquarters are in Miami, Florida, but it has worldwide operations.CCL has lost about 10% of its value since its June 20 earrings release disappointed investors. Concerns were not only about the earnings, but about the guidance as well. Since then, there have been some downgrades and price target reductions.Arnold Donald is the president and chief executive officer of CCL. He has been with the company for almost 20 years. Apparently Mr. Donald believes that this selloff is done. He just made a $1 million investment when he bought 22,000 shares around $45.31.Mr. Donald also made a similar size investment in December when the markets made the significant move lower and CCL was trading around current levels. He must believe that the stock is a good value at these levels. Denbury Resource (DNR)Denbury Resource (NYSE:DNR) is an independent oil and natural gas company involved in exploration, drilling and extraction. The company operates in the Gulf Coast and Rocky Mountain regions.DNR stock has been in a death spiral since October, when it was trading around $6.50 a share. Its most recent close was $1.24. That is an 80% decrease in shareholder value. A lot of this is due to the depreciation in natural gas prices that has occurred since then. There have also been concerns over acquisitions that the company was involved in.Christian Kendall is the president and CEO of Denbury, and he just invested $125,000 of his personal funds when he bought 100,000 shares. * The 7 Top Small-Cap Stocks Of 2019 Wall Street isn't too excited about DNR's future prospects. Currently, 11 firms follow it and the average rating is a hold, according to MarketWatch. Macerich (MAC)Macerich (NYSE:MAC) is real estate investment trust, or REIT. It acquires, manages and develops shopping centers throughout the United States.Some analysts have attributed the share price to the ongoing issues of traditional "brick and mortar" stores suffering from the Amazon (NASDAQ:AMZN) effect. After all, if retail store outlets aren't doing well, they will be closing, and this will in turn have a negative affect on malls and shopping centers.The stock of MAC has lost over 40% of its value over the past year. But two of its insiders think the selloff is overdone because they just made significant investments.Edward Coppola is the president of Macerich. He just invested $165,000 when he paid $32.88 for 5,000 shares. And Andrea Stephen is a director. She just bought 20,000 share at around $32.50. This is an investment of $650,000! Each of these insiders apparently believes that MAC has great future prospects. AbbVie (ABBV)AbbVie (NYSE:ABBV) is a research-based biopharmaceutical company. It develops and sells products that treat conditions such as chronic autoimmune diseasesOver the past year, shares of ABBV stock have lost about 20% of their value. This includes last week's drop of 15%. This dramatic plunge was due to the announcement that ABBV is buying Allergan (NYSE:AGN). Clearly some investors don't think that this deal makes good sense.Three insiders of AbbVie must think that this selling was irrational, though. All three made significant investments.Edward Rapp is a director of the company. He just invested $500,000 when he bought 7,500 shares at $67.30. Roxanne Austin, also a director, just invested $775,000 when she paid $67.50 for 11,500 shares.William Chase is the executive vice-president of finance and administration. He just bought 30,400 shares at a price of $67.30. That's $2 million! * The Top 8 Tech Stocks of 2019 (So Far) These insiders are already profiting. The stock is trading $5 higher than where they bought it. TG Therapeutics (TGTX)TG Therapeutics (NASDAQ:TGTX) is a biopharmaceutical company. It develops treatments for B-cell malignancies and auto immune diseases.Last September, shares of TGTX lost about 65% of their value, dropping from $12.50 to $5.25. This was due to disappointing results in one of their drug trials.The stock traded sideways from then through March when it started to make a recovery. Since then the shares have more than doubled in value.Michael Weiss is the CEO and president of TG Therapeutics. Mr. Weiss must believe that this rally is going to continue. He just bought 50,000 shares at a price of $7.04, an investment of $350,000.Wall Street agrees with Mr. Weiss that this stock is undervalued. According to MarketWatch, the 6 firms that follow it all have buy ratings on it. The average target price is $19, more than 100% higher than the most recent close. GigaMedia (GIGM)GigaMedia (NASDAQ:GIGM) provides digital entertainment services. Through its subsidiary FunTown, it provides online gaming.GigaMedia's customers may be having fun, but this year its shareholders sure haven't been. The prices of the shares have fallen from around $3 to $2.36.I am not sure why the share price has dropped. Chang Ming Huang doesn't seem to know why the price has dropped either. He is the CEO of the company. On June 19 he bought 57,885 shares at $2.50. That is $145,000. He also invested an additional $95,000 earlier in the month. * 7 Stocks to Buy for a Dovish Fed No firms on Wall Street officially follow GIGM, but some investors think that it could be a bullish dynamic when a company isn't followed. This is because if they invest before it is 'discovered' by The Street, they may be in it before the big players get involved and it makes a dramatic move upwards. Calithera Biosciences (CALA)Calithera Biosciences (NASDAQ:CALA) discovers and develops small molecule drugs that are used to treat cancer.Over the past 3 months, shares of CALA have fallen from $6 to $4. Most of this drop occurred in mid-June when the company announced that it was going to issue more shares. It had spiked just before this when they announced positive results from a trial.Maybe they announced the share offering because management felt that they could get a higher price. Investors disagreed and sold the stock. They feel that the negative results of the stock dilution will far outweigh the positives that came from the trial.Susan Molineaux Ph.D is the president and CEO of CALA. Christopher Molineaux Ph.D is Senior Vice-President of Development. And they both seem to believe the stock will rally from current levels because these two insiders each just purchased 50,000 shares at $3.88, a total investment of almost $400,000.As of the time of this writing Mark Putrino did not hold any positions in the aforementioned securities. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 F-Rated Stocks to Sell for Summer * 7 Stocks to Buy for the Same Price as Beyond Meat * 7 Penny Marijuana Stocks That Are NOT Cheap Stocks Compare Brokers The post 7 Stocks on Sale the Insiders Are Buying appeared first on InvestorPlace.
- Zacks•28 days ago
Can Strong Cash Flows Help Prestige Consumer Pare Hurdles?
Prestige Consumer (PBH) gains from prudent buyouts as well as a robust cash position. However, currency fluctuations and persistence of tough retail landscape are worries.
- Zacks•29 days ago
Can Ralph Lauren's Growth Plans Offset Near-Term Headwinds?
Ralph Lauren (RL) gains from the Next Great Chapter plan as well as strength in international and digital businesses. But sluggishness in the North America segment and currency remain deterrents.
- Simply Wall St.•last month
Read This Before Judging Guess', Inc.'s (NYSE:GES) ROE
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- Simply Wall St.•last month
Can Guess', Inc. (NYSE:GES) Improve Its Returns?
Many investors are still learning about the various metrics that can be useful when analysing a stock. This article is...
- Zacks•last month
lululemon Launches Selfcare Products, Teams Up With Sephora
lululemon (LULU) announces the launch of Selfcare line of personal care products like deodorants, moisturizers, shampoos and lip balm.
- GuruFocus.com•last month
Why Guess? Is a Bargain
The company’s strategy could lead to a stock price recovery
- GuruFocus.com•last month
Guess? Inc (GES) CEO and Director Carlos Alberini Bought $5 million of Shares
CEO and Director of Guess? Inc (NYSE:GES) Carlos Alberini bought 347,353 shares of GES on 06/13/2019 at an average price of $14.32 a share.
- Zacks•last month
lululemon (LULU) Stock Rises on Q1 Earnings & Sales Beat
lululemon (LULU) beats first-quarter fiscal 2019 earnings and sales estimates on strong business momentum and execution of growth strategies. This momentum is likely to continue in fiscal 2019.
- Thomson Reuters StreetEvents•last month
Edited Transcript of GES earnings conference call or presentation 6-Jun-19 8:45pm GMT
Q1 2020 Guess" Inc Earnings Call
- MarketWatch•last month
Retailers including Walmart warned the trade war will cost U.S. households — JPMorgan says it already is
JPMorgan analysts say the cost of tariffs on Chinese goods could rise from the $600 it’s already imposing on U.S. households, buttressing the warnings from retailers like Walmart Inc. and Target Corp.
- Motley Fool•2 months ago
Why DocuSign, Guess?, and American Equity Investment Life Slumped Today
Even on a positive day for the market, some companies had to deal with bad news.
- Yahoo Finance Video•last month
Crocs to cut production in China, citing Trump's tariff threat
Retailer Crocs will cut production in China as the company tries to ease the potential impact of President Trump's tariffs. The goal will be to source about 10% of products from China by 2020. Yahoo Finance's Seana Smith, Dan Roberts, Dan Howley and Jared Blikre discuss.
